Comparison
Glucagon vs. Lixisenatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
16941-32-5
320367-13-3
Molecular weight
3483 g/mol
4858.5 g/mol
Half-life
0.13 h
3 h
Sequence
HSQGTFTSDYSKYLDSRRAQDFVQWLMNTHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2Mechanism of action
Glucagon
Glucagon is produced in the alpha cells of the pancreas (islets of Langerhans) and released when blood sugar is low. Glucagon binds the glucagon receptor (GCGR), a G-protein-coupled receptor expressed predominantly on hepatocytes. Activation stimulates adenylate cyclase, raises cyclic AMP and activates protein kinase A. This drives glycogenolysis (breakdown of hepatic glycogen into glucose) and gluconeogenesis (de novo glucose synthesis), which raises blood glucose. Glucagon also promotes lipolysis. As the counterpart to insulin it contributes to glucose homeostasis. It transiently relaxes gastrointestinal smooth muscle, which is the basis of its diagnostic use in imaging.
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
4
5
Effects recorded
4
3
Open conflicts
1
1
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Glucagon and Lixisenatide?
- Glucagon is classified as "Metabolic", while Lixisenatide is classified as "Metabolic". Glucagon: Glucagon is a 29-amino-acid pancreatic hormone produced by the alpha cells of the islets of Langerhans. It is the physiological counterpart to insulin and raises blood glucose via hepatic glycogenolysis and gluconeogenesis. It is approved as an emergency treatment for severe hypoglycaemia and as a diagnostic aid; its receptor is also a target of modern dual and triple incretin agonists. Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Glucagon or Lixisenatide?
- The highest available evidence level is "Human RCT" for Glucagon and "Human RCT" for Lixisenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Glucagon and Lixisenatide in Germany and the United States?
- Germany: Glucagon — Prescription, Lixisenatide — Prescription. United States: Glucagon — Prescription, Lixisenatide — Unapproved. These are factual summaries with source and review date on the individual pages.